Business Context and Reporting Period
This Form 8-K filing by Spero Therapeutics, Inc. (SPRO) reports a significant management transition effective August 1, 2023. The report was filed on June 14, 2023, detailing the departure of the Chief Executive Officer and the appointment of new leadership for the executive team and Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements and consulting fees associated with the leadership transition.
- Outgoing CEO Compensation: Dr. Ankit Mahadevia will receive a pro-rata 2023 bonus (subject to Board discretion) and COBRA health premium coverage until January 31, 2024.
- Consulting Fees (Outgoing CEO): $54,000 per month from the transition date through January 31, 2024; thereafter, $310 per hour through July 31, 2025.
- New CEO Compensation: Satyavrat Shukla will receive an annual base salary of $575,000 and a target annual bonus of 50% of base salary. He will also receive 266,000 restricted stock units (RSUs) vesting over four years.
- Interim CFO Services: The Company will pay Danforth Advisors an hourly rate of $650 for finance, accounting, and administrative services, including Interim CFO duties provided by Stephen J. DiPalma.
Material Changes Versus Prior Period
The filing details a complete restructuring of the Company's top executive and Board leadership:
- CEO Transition: Dr. Ankit Mahadevia stepped down as CEO and President to become Chairman of the Board and a consultant. Satyavrat Shukla, formerly CFO, was appointed CEO and President.
- CFO Transition: Mr. Shukla ceased serving as CFO. Stephen J. DiPalma was appointed Interim CFO and Treasurer.
- Board Composition: The Board size increased to nine directors. Mr. Shukla was appointed as a Class II director. Dr. Milind Deshpande stepped down as Chairman but remains a Class III director. Dr. Mahadevia was appointed Chairman. Dr. Patrick Vink was elected Lead Director.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, operational outlook, or specific risk factors beyond the standard disclosures regarding the transition.
- Reason for Departure: Dr. Mahadevia's departure is for personal reasons and is not related to any disagreement with the Company.
- Severance Provisions: Mr. Shukla's employment agreement includes severance of 12 months' base salary plus a pro-rated bonus for termination without Cause or for Good Reason. In the event of a Change of Control within specific windows, severance increases to 18 months' base salary plus 1.5x the target bonus, with full equity acceleration.
- Equity Vesting: Dr. Mahadevia's equity awards will fully vest in the event of a Change of Control if he remains on the Board. His existing awards continue to vest under the consulting agreement terms.
Key Facts for Investor Verification
- Verify the effective date of the leadership transition (August 1, 2023) and the immediate impact on strategic execution.
- Review the full text of the Transition and Separation Agreement and the Amended Employment Agreement (to be filed as exhibits to the Q2 2023 10-Q) for detailed vesting schedules and termination conditions.
- Assess the financial impact of the new compensation structure, including the $575,000 base salary for the new CEO and the $650/hour consulting fee for the Interim CFO.
- Monitor the Company's ability to recruit a permanent CFO following the interim appointment of Stephen J. DiPalma.